December 3, 2025 07:20 AM EST Updated 02:27 PM R&D Up­dat­ed: Phar­varis’ hered­i­tary an­gioede­ma drug gets Phase 3 win Elizabeth Cairns Senior biopharma journalist Phar­varis’ on-de­mand oral treat­ment for hered­i­tary an­gioede­ma (HAE) at­tacks al­le­vi­at­ed symp­toms sig­nif­i­cant­ly faster than place­bo, ac­cord­ing to topline da­ta from a Phase 3 tri­al … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER ENDPOINTS CAREERS Analyst – Life Sciences Strategy & Intelligence Sedulo Group Remote VIEW JOB OFFER post your job now